Form 4: Vaxcyte COO Jim Wassil Sells Shares Under 10b5-1 Plan and Transfers Shares Due to Divorce Settlement

Vaxcyte's Chief Operating Officer, Jim Wassil, executed stock sales under a pre-arranged 10b5-1 trading plan and transferred shares to his ex-spouse as part of a divorce settlement.

Summary

• Jim Wassil, the Chief Operating Officer of Vaxcyte, Inc., filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
• On May 1, 2024, Wassil sold shares of common stock in three separate transactions at weighted-average prices of $61.227, $61.993, and $63.646.
• These sales were executed under a Rule 10b5-1 trading plan adopted on May 23, 2023.
• Wassil also transferred 3,378 shares to his ex-spouse pursuant to a divorce settlement agreement.
• Following these transactions, Wassil directly owns 215,462 shares of Vaxcyte common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the stock sales were pre-planned under a 10b5-1 trading plan and a portion of the transaction was related to a divorce settlement, not necessarily reflecting a change in the executive's view of the company's prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, allowing investors to track executive sentiment and potential alignment with company performance.

Stakeholder Impact

• The stock sales by a key executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.
• The transfer of shares due to the divorce settlement has no direct impact on the company's operations or financial performance.

Key Dates